Talk:Cancer treatment

This is the talk page for discussing improvements to the Cancer treatment article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1

Medicine: Hematology-oncology Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Hematology-oncology task force.

Please update section "Research"

Please update the section with info from/about these or some of these studies / their researched categories of experimental treatments. They are currently included in 2022 in science like so:

Progress in the treatment of cancer:
A very small trial shows complete remission of a type of colorectal cancer without surgery and radiation in all 12 patients.^[1]^[2] On the same day, results of a trial show that trastuzumab deruxtecan therapy for HER2-low metastatic breast cancer exceeded results from chemotherapy.^[3]^[4] The synthesis of ERX-41, a novel compound that has shown promise in eliminating cancer cells, is reported (2 June).^[5] Researchers describe a new light-activated 'photoimmunotherapy' for brain cancer in vitro. They believe it could join surgery, chemotherapy, radiotherapy and immunotherapy as a fifth major form of cancer treatment (16 June).^[6]^[7]

There's probably also quite a few other types / categories of treatments described/demonstrated to notable level in trials/studies that are missing.

The top of the section section could also have some more info about how, who, where, to what extent, by what means and why such treatments are studied – for example how it's funded, the needs/motivations for doing so, metascience identified problems & open questions such as reproducibility issues, 21st Century Cures Act#Medical research and diagrams (maybe via Scholia or OpenAlex). This could all go into a new subsection.

Please also see my related & similar proposal at Talk:Cancer biomarker#Please update with info on new biomarkers

I'd suggest some publicly-funded non-profit independent cancer-related organization/researcher (e.g. NHS, WHO, NCI, EORTC, etc) gets tasked with non-authoritatively (very independently) updating, maintaining and cleaning the article but other people could do this (instead of only additionally) too.

It is missing info on useful/efficacious/potentially efficacious sometimes well-researched options of "Complementary and alternative treatments". If they are only useful in combination and/or in combination with more conventional/more intensive treatments they can be informed about in this section. This could include (various ultimately specific applications of) AMPK and cancer, and Diet and cancer.

The article should probably get far more views from people interested in this which I think are far more than the ~4000 per month currently reading the article. Not sure how it would be achieved, maybe increasing the quality of the article makes it more visible to search engines. It may also require good redirects, wikilinks from other articles like Cancer, and so on instead or additionally too.

Maybe transcluding the first paragraph of most sections of Experimental cancer treatment would be a good solution here, at least it would be good to not leave out various specific experimental treatments instead of at least naming them and not to have relatively excessive details on some other specific treatments. Short sections for the most advanced treatments in research and bullet-point list of the remaining ones would be the solution I think would be best.

Please comment what you think below. I also posted about this at Talk:Experimental cancer treatment.

References

^ Osborne, Margaret. "Small Cancer Trial Resulted in Complete Remission for All Participants". Smithsonian Magazine. Retrieved 21 July 2022.
^ Cercek, Andrea; Lumish, Melissa; Sinopoli, Jenna; Weiss, Jill; Shia, Jinru; Lamendola-Essel, Michelle; El Dika, Imane H.; Segal, Neil; Shcherba, Marina; Sugarman, Ryan; Stadler, Zsofia; Yaeger, Rona; Smith, J. Joshua; Rousseau, Benoit; Argiles, Guillem; Patel, Miteshkumar; Desai, Avni; Saltz, Leonard B.; Widmar, Maria; Iyer, Krishna; Zhang, Janie; Gianino, Nicole; Crane, Christopher; Romesser, Paul B.; Pappou, Emmanouil P.; Paty, Philip; Garcia-Aguilar, Julio; Gonen, Mithat; Gollub, Marc; Weiser, Martin R.; Schalper, Kurt A.; Diaz, Luis A. (23 June 2022). "PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer". New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. ISSN 0028-4793. PMID 35660797. S2CID 249395846.
^ "Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy in Previously Treated HER2-Low Unresectable or Metastatic Breast Cancer". www.esmo.org. Retrieved 21 July 2022.
^ Modi, Shanu; Jacot, William; Yamashita, Toshinari; Sohn, Joohyuk; Vidal, Maria; Tokunaga, Eriko; Tsurutani, Junji; Ueno, Naoto T.; Prat, Aleix; Chae, Yee Soo; Lee, Keun Seok; Niikura, Naoki; Park, Yeon Hee; Xu, Binghe; Wang, Xiaojia; Gil-Gil, Miguel; Li, Wei; Pierga, Jean-Yves; Im, Seock-Ah; Moore, Halle C. F.; Rugo, Hope S.; Yerushalmi, Rinat; Zagouri, Flora; Gombos, Andrea; Kim, Sung-Bae; Liu, Qiang; Luo, Ting; Saura, Cristina; Schmid, Peter; Sun, Tao; Gambhire, Dhiraj; Yung, Lotus; Wang, Yibin; Singh, Jasmeet; Vitazka, Patrik; Meinhardt, Gerold; Harbeck, Nadia; Cameron, David A. (5 June 2022). "Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer". New England Journal of Medicine. 387 (1): 9–20. doi:10.1056/NEJMoa2203690. PMID 35665782. S2CID 249418284.
^ Liu, Xihui; Viswanadhapalli, Suryavathi; Kumar, Shourya; Lee, Tae-Kyung; Moore, Andrew; Ma, Shihong; Chen, Liping; Hsieh, Michael; Li, Mengxing; Sareddy, Gangadhara R.; Parra, Karla; Blatt, Eliot B.; Reese, Tanner C.; Zhao, Yuting; Chang, Annabel; Yan, Hui; Xu, Zhenming; Pratap, Uday P.; Liu, Zexuan; Roggero, Carlos M.; Tan, Zhenqiu; Weintraub, Susan T.; Peng, Yan; Tekmal, Rajeshwar R.; Arteaga, Carlos L.; Lippincott-Schwartz, Jennifer; Vadlamudi, Ratna K.; Ahn, Jung-Mo; Raj, Ganesh V. (2 June 2022). "Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress". Nature: 1–19. doi:10.1038/s43018-022-00389-8. PMID 35654861. S2CID 249312892.
^ "Scientists harness light therapy to target and kill cancer cells in world first". The Guardian. 17 June 2022. Retrieved 21 June 2022.
^
Mączyńska, Justyna; Raes, Florian; Da Pieve, Chiara; Turnock, Stephen; Boult, Jessica K. R.; Hoebart, Julia; Niedbala, Marcin; Robinson, Simon P.; Harrington, Kevin J.; Kaspera, Wojciech; Kramer-Marek, Gabriela (21 January 2022). "Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy". BMC Medicine. 20 (1): 16. doi:10.1186/s12916-021-02213-z. ISSN 1741-7015.{{cite journal}}: CS1 maint: unflagged free DOI (link)
- News release: "Light-activated 'photoimmunotherapy' could enhance brain cancer treatment". Institute of Cancer Research. 16 June 2022. Retrieved 21 June 2022.

Prototyperspective (talk) 14:48, 3 August 2022 (UTC)[reply]

Wiki Education assignment: Technical and Scientific Communication

This article was the subject of a Wiki Education Foundation-supported course assignment, between 22 August 2022 and 9 December 2022. Further details are available on the course page. Student editor(s): Estehman (article contribs).

— Assignment last updated by Estehman (talk) 15:20, 21 September 2022 (UTC)[reply]

Wiki Education assignment: General Biology I Honors

This article was the subject of a Wiki Education Foundation-supported course assignment, between 31 August 2022 and 16 December 2022. Further details are available on the course page. Student editor(s): Anoshah04 (article contribs). Peer reviewers: SandersKathryn, Stephkow1029, Jand1990, Avengers2015, Kkio77, Sprygrocki.

— Assignment last updated by Stephkow1029 (talk) 17:28, 29 November 2022 (UTC)[reply]

Wiki Education assignment: STS 1010

This article was the subject of a Wiki Education Foundation-supported course assignment, between 11 January 2023 and 5 May 2023. Further details are available on the course page. Student editor(s): Jaclure (article contribs). Peer reviewers: Cbshealy13, Liviaamurphy444, Wmquinn.

— Assignment last updated by Jessicacariello (talk) 14:56, 14 February 2023 (UTC)[reply]

[1] Osborne, Margaret. "Small Cancer Trial Resulted in Complete Remission for All Participants". Smithsonian Magazine. Retrieved 21 July 2022.

[2] Cercek, Andrea; Lumish, Melissa; Sinopoli, Jenna; Weiss, Jill; Shia, Jinru; Lamendola-Essel, Michelle; El Dika, Imane H.; Segal, Neil; Shcherba, Marina; Sugarman, Ryan; Stadler, Zsofia; Yaeger, Rona; Smith, J. Joshua; Rousseau, Benoit; Argiles, Guillem; Patel, Miteshkumar; Desai, Avni; Saltz, Leonard B.; Widmar, Maria; Iyer, Krishna; Zhang, Janie; Gianino, Nicole; Crane, Christopher; Romesser, Paul B.; Pappou, Emmanouil P.; Paty, Philip; Garcia-Aguilar, Julio; Gonen, Mithat; Gollub, Marc; Weiser, Martin R.; Schalper, Kurt A.; Diaz, Luis A. (23 June 2022). "PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer". New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. ISSN 0028-4793. PMID 35660797. S2CID 249395846.

[3] "Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy in Previously Treated HER2-Low Unresectable or Metastatic Breast Cancer". www.esmo.org. Retrieved 21 July 2022.

[4] Modi, Shanu; Jacot, William; Yamashita, Toshinari; Sohn, Joohyuk; Vidal, Maria; Tokunaga, Eriko; Tsurutani, Junji; Ueno, Naoto T.; Prat, Aleix; Chae, Yee Soo; Lee, Keun Seok; Niikura, Naoki; Park, Yeon Hee; Xu, Binghe; Wang, Xiaojia; Gil-Gil, Miguel; Li, Wei; Pierga, Jean-Yves; Im, Seock-Ah; Moore, Halle C. F.; Rugo, Hope S.; Yerushalmi, Rinat; Zagouri, Flora; Gombos, Andrea; Kim, Sung-Bae; Liu, Qiang; Luo, Ting; Saura, Cristina; Schmid, Peter; Sun, Tao; Gambhire, Dhiraj; Yung, Lotus; Wang, Yibin; Singh, Jasmeet; Vitazka, Patrik; Meinhardt, Gerold; Harbeck, Nadia; Cameron, David A. (5 June 2022). "Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer". New England Journal of Medicine. 387 (1): 9–20. doi:10.1056/NEJMoa2203690. PMID 35665782. S2CID 249418284.

[5] Liu, Xihui; Viswanadhapalli, Suryavathi; Kumar, Shourya; Lee, Tae-Kyung; Moore, Andrew; Ma, Shihong; Chen, Liping; Hsieh, Michael; Li, Mengxing; Sareddy, Gangadhara R.; Parra, Karla; Blatt, Eliot B.; Reese, Tanner C.; Zhao, Yuting; Chang, Annabel; Yan, Hui; Xu, Zhenming; Pratap, Uday P.; Liu, Zexuan; Roggero, Carlos M.; Tan, Zhenqiu; Weintraub, Susan T.; Peng, Yan; Tekmal, Rajeshwar R.; Arteaga, Carlos L.; Lippincott-Schwartz, Jennifer; Vadlamudi, Ratna K.; Ahn, Jung-Mo; Raj, Ganesh V. (2 June 2022). "Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress". Nature: 1–19. doi:10.1038/s43018-022-00389-8. PMID 35654861. S2CID 249312892.

[6] "Scientists harness light therapy to target and kill cancer cells in world first". The Guardian. 17 June 2022. Retrieved 21 June 2022.

[7] Mączyńska, Justyna; Raes, Florian; Da Pieve, Chiara; Turnock, Stephen; Boult, Jessica K. R.; Hoebart, Julia; Niedbala, Marcin; Robinson, Simon P.; Harrington, Kevin J.; Kaspera, Wojciech; Kramer-Marek, Gabriela (21 January 2022). "Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy". BMC Medicine. 20 (1): 16. doi:10.1186/s12916-021-02213-z. ISSN 1741-7015.{{cite journal}}: CS1 maint: unflagged free DOI (link)
News release: "Light-activated 'photoimmunotherapy' could enhance brain cancer treatment". Institute of Cancer Research. 16 June 2022. Retrieved 21 June 2022.

[8] News release: "Light-activated 'photoimmunotherapy' could enhance brain cancer treatment". Institute of Cancer Research. 16 June 2022. Retrieved 21 June 2022.

[1]

[2]

[3]

[4]

[5]

[6]

[7]